Financial Performance - The company reported a net loss of $41.9 million for the three months ended September 30, 2024, compared to a net loss of $35.5 million for the same period in 2023, reflecting an increase of $6.4 million [81]. - The company had an accumulated deficit of $267.2 million as of September 30, 2024 [81]. - The company expects to continue incurring significant net operating losses as it advances product candidates through clinical development and seeks regulatory approvals [81]. - The company has not generated any revenue from product sales since inception and does not expect to do so until regulatory approval is obtained for its product candidates [82]. - Cash used in operating activities for the nine months ended September 30, 2024, was $104.9 million, primarily due to a net loss of $122.1 million [114]. - Cash used in operating activities for the nine months ended September 30, 2023, was $52.2 million, attributed to a net loss of $66.1 million [115]. - The company may need to raise substantial additional capital to continue operations and achieve profitability [112]. Expenses - Research and development expenses increased to $35.9 million for the three months ended September 30, 2024, up from $22.2 million in the same period of 2023, representing a rise of $13.7 million [96]. - General and administrative expenses rose to $11.2 million for the three months ended September 30, 2024, compared to $6.5 million in the prior year, an increase of $4.7 million [96]. - Total operating expenses for the three months ended September 30, 2024, were $47.1 million, up from $28.7 million in the same period of 2023, marking an increase of $18.4 million [96]. - For the nine months ended September 30, 2024, research and development expenses totaled $103.9 million, a significant increase of $55.2 million from $48.7 million in 2023 [103]. - General and administrative expenses for the nine months ended September 30, 2024, were $33.3 million, up $20.3 million from $13.0 million in 2023 [104]. - The increase in research and development expenses was primarily driven by a $24.8 million rise in manufacturing and technical operations costs for the nine months ended September 30, 2024 [103]. Cash and Liquidity - Cash and cash equivalents, along with marketable securities, totaled $404.8 million as of September 30, 2024, expected to be sufficient to meet working capital needs through 2026 [81]. - The company anticipates that its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs through 2026 [110]. - Cash flows for the nine months ended September 30, 2024, resulted in a net decrease in cash and cash equivalents of $334.6 million [113]. - Total fixed lease payment obligations outstanding as of September 30, 2024, are $45.3 million, with $3.1 million payable within the next 12 months [119]. - The company has entered into lease arrangements for facilities through March 31, 2031, impacting future liquidity and cash flows [119]. Financing Activities - Cash provided by financing activities for the nine months ended September 30, 2024, was $103.6 million, consisting of $102.9 million in net proceeds from the issuance of common stock [117]. - The company expects to fund operations through public or private equity offerings or debt financings until significant product revenue is generated [112]. Clinical Development - The company is advancing its lead program, firicabtagene autoleucel (firi-cel), in a potentially pivotal Phase 2 clinical trial for patients with large B-cell lymphoma (LBCL) who are refractory to CD19 CAR T-cell therapy [79]. - The company is developing CRG-023, a tri-specific CAR T designed to target multiple B-cell lineage antigens, aiming to provide durable responses for a broader range of B-cell malignancies [79]. - Interest income surged to $5.4 million for the three months ended September 30, 2024, up from $0.9 million in 2023, reflecting a $4.5 million increase due to higher cash balances [99]. - Interest income for the nine months ended September 30, 2024, reached $15.4 million, a $13.8 million increase from $1.6 million in 2023 [105].
Cargo Therapeutics(CRGX) - 2024 Q3 - Quarterly Report